You're on Mounjaro: here's what the evidence says about what comes next

What's actually happening in your body on tirzepatide

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity across 72 weeks. By the end, participants on the 15mg dose had lost an average of around 20–21% of their body weight. That figure is worth holding onto, not because it predicts your outcome, but because it reflects what happens when the medicine is given time to work at its full therapeutic dose. The first few weeks are different.

Tirzepatide activates both GIP and GLP-1 receptors, which together slow gastric emptying and reduce hunger signals coming from the gut. When food moves through your stomach more slowly, you feel full faster and stay full longer. You may also notice that foods you used to crave feel less compelling. This isn't willpower; it's the pharmacology. Understanding how tirzepatide works can make those changes feel less disorientating when they arrive.

The starter dose (2.5mg) exists to let your digestive system acclimatise. It's not the dose that drives weight loss; your prescriber will move you up through 5mg, 7.5mg and beyond in steps, typically four weeks apart, watching how you tolerate each level. Most people feel the appetite effects more clearly from 5mg onward. One practical habit worth building early: weigh yourself at the same time each week, in the same clothes, before eating, it removes noise from the trend and gives your clinical team useful data at every review.

Side effects you may encounter while on Mounjaro, and what they mean

Nausea is the most frequently reported side effect in the SURMOUNT programme, followed by diarrhoea, constipation, vomiting, indigestion and burping. These are not signs that the medicine is harming you, they reflect the same gastric-slowing mechanism that makes the treatment work. Most people find the symptoms peak in the first week or two after starting or increasing a dose, then settle.

Eating smaller portions, avoiding high-fat meals and staying well hydrated all help. Keeping upright for a while after eating is a simple adjustment many patients find useful. If symptoms are severe or persistent, contact your prescriber rather than pushing through alone.

There are symptoms that require urgent medical attention. Severe, persistent abdominal pain that radiates toward your back (particularly with vomiting) should prompt you to seek help the same day. In January 2026, the MHRA issued a Drug Safety Update specifically flagging acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines; the Yellow Card scheme is the right place to report anything unexpected. Signs of a serious allergic reaction, gallbladder symptoms, or sudden changes in vision (in people with diabetes) are also reasons to call rather than wait.

If you're picking up a minor illness (say, a cold or viral infection while on Mounjaro) that's worth knowing about too, since hydration becomes more important when you're already prone to GI symptoms.

Eligibility, ongoing clinical oversight, and what being reviewed actually involves

The UK licence for Mounjaro covers adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. NICE's appraisal of tirzepatide (TA1026, published in December 2024) sets out NHS eligibility criteria, which are stricter and phased in over time. Private prescribing follows the licensed indication; your prescriber still assesses the full picture, not just your BMI.

Being on Mounjaro doesn't mean the clinical work is done. Each repeat supply should involve a review: your weight trend, how you're tolerating the current dose, any new medicines or health changes, and whether it makes sense to increase. At nume, a GPhC-registered prescriber reads every repeat request, a real clinician, not an automated system. If you're thinking about whether treatment is right for you in the first place, the eligibility considerations for Mounjaro are worth reading in full.

Women using oral contraceptives should be aware that tirzepatide may reduce how well the pill is absorbed, particularly in the first four weeks of treatment and for four weeks after each dose increase. Adding a barrier method during those windows is the guidance from NHS England. If you take HRT, ask your prescriber about transdermal options for the same reason.

Making the most of treatment while you're on it

The trial evidence is consistent: tirzepatide works best alongside a reduced-calorie diet and increased physical activity, that's a condition of its UK licence, not a caveat. The NHS patient information for tirzepatide sets this out clearly. In practice, the appetite reduction Mounjaro produces makes eating less feel more achievable than it did before treatment; the opportunity is to use that window to build habits that outlast the prescription.

Protein is worth prioritising. When calorie intake falls sharply, muscle loss is a real risk, and adequate protein alongside some resistance exercise helps protect lean mass. Hydration matters more than many people expect, slower gastric emptying can make it easier to forget to drink, and dehydration compounds nausea. If you want a fuller picture of how Mounjaro fits into a weight management plan, that's a good place to start before your next review. Small, regular meals beat large infrequent ones in the early months.

If you have questions about specific interactions (for example, whether senna is safe alongside Mounjaro) it's always better to ask your prescriber or pharmacist directly rather than assume. For those already on the programme and moving through their dose increases, guidance on the next stage of Mounjaro treatment covers what to expect as you progress. The treatment landscape is covered more broadly on our weight-loss treatment overview, and if you'd like to discuss your current plan with a prescriber, you can check your eligibility and speak to the team.